Table 1 Treatment and outcome of 42 CML patients with myeloid sarcoma

From: Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

No.	Sex	Age	MS subgroups	Post-MS treatment	Response of MS ^a	Response of CML ^a	F/U time ^b (months)	Status at last F/U	Cause of Death	ABL mutations
1	M	72.7	MS1-CP	TKI	PR	SD	20.5	Dead	Leukemia PD, MS PD	No^c
2	M	47.8	MS1-CP	CT+TKI+RT	CR	SD	26.9	Dead	Leukemia PD	NT
3	M	50.0	MS1-CP	CT+TKI Allo-HSCT	CR	MMR	27.0	Dead	GvHD	NT
4	M	52.3	MS1-CP	CT+TKI	CR	CCyR	36.0	Dead	Leukemia PD, MS PD	T315I^c
5	M	30.3	MS1-CP	CT+TKI	NA	NA	6.2	Alive		NT
6	F	63.5	MS1-CP	TKI	CR	MMR	14.4	Alive		NT
7	M	30.7	MS1-CP	TKI	CR	CCyR	14.3	Alive		NT
8	M	72.8	MS1-CP	TKI	CR	MMR	22.8	Alive		NT
9	M	29.2	MS1-CP	CT+TKI	CR	CMR	22.8	Alive		NT
10	M	52.7	MS1-CP	CT+TKI	CR	MMR	27.8	Alive		NT
11	F	23.3	MS1-CP	CT+TKI Allo-HSCT	CR	CMR	118.8	Alive		NT
12	M	52.7	MS1-CP	CT+TKI Allo-HSCT	CR	CMR	140.9	Alive		NT
13	M	45.3	MS1-CP	CT+TKI+RT	CR	CMR	146.6	Alive		No^c
14	M	36.3	MS2-CP^d	CT+TKI	PD	PD	0.8	Dead	Leukemia PD, MS PD	No
15	M	26.8	MS2-CP	CT+TKI	PD	PD	0.9	Dead	Leukemia PD, MS PD	NT
16	M	75.1	MS2-CP	TKI	PR	PD	2.1	Dead	Leukemia PD	NT
17	M	51.0	MS2-CP^d	CT+TKI+RT	PR	PD	2.4	Dead	Leukemia PD	No
18	M	23.2	MS2-CP	CT+TKI	PR	PD	4.2	Dead	Leukemia PD, MS PD	No
19	M	47.8	MS2-CP^d	CT+TKI Allo-HSCT	CR	CCyR	4.9	Dead	Leukemia PD	T315I
20	M	23.5	MS2-CP	CT+TKI	CR	CHR	6.5	Dead	Leukemia PD	E255V
21	M	55.5	MS2-CP	CT+TKI	CR	CCyR	7.5	Dead	Leukemia PD, MS PD	NT
22	F	51.7	MS2-CP	CT	NA	NA	8.3	Dead	NA	NT
23	M	51.3	MS2-CP	CT+TKI	PR	SD	10.1	Dead	Leukemia PD, MS PD	NT
24	M	43.1	MS2-CP	CT+TKI+RT	PR	SD	13.9	Dead	Leukemia PD	E255K
25	M	51.4	MS2-CP	TKI+RT	CR	CCyR	18.4	Dead	Leukemia PD, MS PD	NT
26	F	48.4	MS2-CP^d	TKI	CR	MMR	21.7	Dead	Leukemia PD,	NT
27	M	57.3	MS2-CP	CT+TKI Allo-HSCT	CR	CMR	88.5	Dead	Esophageal cancer	No
28	F	39.2	MS2-CP	CT+TKI	CR	CHR	17.8	Alive		NT
29	F	58.4	MS2-CP	TKI	CR	MMR	64.4	Alive		NT
30	M	56.1	MS2-CP	TKI	CR	CMR	126.9	Alive		NT
31	M	19.4	MS2-BP	CT+TKI	PD	PD	0.8	Dead	Leukemia PD	E255V/K
32	M	82.7	MS2-BP	CT+TKI	PD	PD	2.0	Dead	Leukemia PD	NT
33	M	45.8	MS2-BP	CT+TKI	PD	PD	0.6	Dead	Leukemia PD, MS PD	No
34	F	31.9	MS2-BP	CT+TKI+RT Allo-HSCT	PR	CHR	5.2	Dead	Leukemia PD	No
35	M	53.4	MS2-BP	CT+TKI	PD	PD	7.4	Dead	Leukemia PD	NT
36	M	53.2	MS2-BP	CT+TKI	CR	PD	8.7	Dead	Leukemia PD	F317L
37	M	54.3	MS2-BP	CT+TKI Allo-HSCT	CR	CCyR	9.7	Dead	Leukemia PD	No
38	M	34.9	MS2-BP	CT+TKI	CR	MMR	13.6	Dead	Infection	E255
39	M	38.4	MS2-BP	CT	NA	NA	15.7	Alive		NT
40	M	22.0	MS2-BP	CT	NA	NA	0.5	Alive^e		NT
41	F	59.0	MS2-BP	CT	NA	NA	1.0	Alive^e		NT
42	M	44.3	MS2-BP	CT+TKI Allo-HSCT	CR	MMR	28.9	Alive		NT

Abbreviations: age, age at diagnosis of MS; allo-HSCT, allogeneic hematopoietic stem cell transplantation; BP, blast phase; CCyR, complete cytogenetic response; CHR, complete hematologic response; CML, chronic myelogenous leukemia; CP, chronic phase; CR, complete response; CT, chemotherapy; F, female; F/U, follow-up; GvHD, graft-vs-host disease; M, male; MMR, major molecular response; MS, myeloid sarcoma; MS1, MS at initial diagnosis of CML; MS2, MS arising during course of treatment; NA, not applicable; NT, not tested; PD, progressive disease; PR, partial remission; RT, radiation treatment; SD, stable disease; TKI, tyrosine kinase inhibitor. CR of MS was defined as complete disappearance of the lesion(s). PR of MS was defined as decreased size but not complete disappearance of the lesion(s). CHR, CCyR and MMR are defined according to the NCCN and European LeukemiaNet Guidelines.
^aThe best initial response of extramedullary and medullary disease after MS emergence.
^bThe follow-up time after MS emergence.
^cABL mutations detected after MS emergence.
^dThe patients had a history of CML-BP but reverted to CP status when MS2 developed.
^eLost F/U after one course of treatment.

Back to article page

Table 1 Treatment and outcome of 42 CML patients with myeloid sarcoma

Search

Quick links